|Bid||0.0000 x 900|
|Ask||0.0000 x 1000|
|Day's Range||4.4400 - 4.8400|
|52 Week Range||2.6200 - 26.7000|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ORIC
Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the latter's ADX-914 for treating autoimmune diseases.
Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023 Cash and investments of $237.8 million expected to fund current operating plan into 2H 2024 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeu
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...